The DILfrequency study is an adaptive trial to identify optimal IL-2 dosing in patients with type 1 diabetes. (2018)

First Author: Seelig E
Attributed to:  Adaptive Clinical Trials funded by MRC


No abstract provided

Bibliographic Information

Digital Object Identifier:

PubMed Identifier: 30282826

Publication URI:

Type: Journal Article/Review

Volume: 3

Parent Publication: JCI insight

Issue: 19

ISSN: 2379-3708